Catalog No.
FHE43420
Species reactivity
Human
Host species
Mouse
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
Unconjugated
Target
CD158 antigen-like family member A, KIR2DL1, Killer cell immunoglobulin-like receptor 2DL1, Natural killer-associated transcript 1, NKAT-1, MHC class I NK cell receptor, CD158A, p58 natural killer cell receptor clones CL-42/47.11, CD158a, p58.1 MHC class-I-specific NK receptor, NKAT1, p58 NK receptor CL-42/47.11, p58 NK receptor CL-43, NKAT-6, NKAT6, MHC class I NK cell receptor, CD158 antigen-like family member B1, CD158b1, p58 natural killer cell receptor clone CL-43, Natural killer-associated transcript 6, CD158B1, KIR2DL2, Killer cell immunoglobulin-like receptor 2DL2, P58 natural killer cell receptor clones CL-39/CL-17, CD158i, MHC class I NK cell receptor, CD158I, p58 NK receptor CL-39/CL-17, NKAT8, KKA3, NKAT-8, CD158 antigen-like family member I, Killer cell immunoglobulin-like receptor 2DS4, Natural killer-associated transcript 8, KIR2DS4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P43626, P43627, P43632
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
NKVFS1
Alloreactive adaptive natural killer cells in renal transplantation: potential contribution to allograft microvascular inflammation., PMID:40340029
CD94-driven in vitro expansion of highly functional adaptive NKG2C+ NKG2A- CD57+ NK cells from CMV+ healthy donors., PMID:39958331
Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases., PMID:39559361
The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression., PMID:39540437
High-dimensional analysis of NK cells in kidney transplantation uncovers subsets associated with antibody-independent graft dysfunction., PMID:39388279
Conformational Alterations of the Cell Surface of Monomeric and Dimeric β2m-Free HLA-I (Proto-HLA) May Enable Novel Immune Functions in Health and Disease., PMID:39057057
HLA and KIR genetic association and NK cells in anti-NMDAR encephalitis., PMID:39050850
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors., PMID:38993289
IFNγ mediates the resistance of tumor cells to distinct NK cell subsets., PMID:38955423
The investigation of killer-cell immunoglobulin-like receptors (KIRs) and their HLA ligands in Iranian patients with myasthenia gravis., PMID:38422742
Impact of Natural Killer Cell-Associated Factors on Acute Leukemia Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation with αβ T Cell Depletion in a Pediatric Cohort., PMID:38278183
KIR2DS1 and KIR2DL1-C245 Dominantly Repress NK Cell Degranulation Triggered by Monoclonal or Bispecific Antibodies, whereas Education by Uptuning Inhibitory Killer Ig-related Receptors Exerts No Advantage in Ab-dependent Cellular Cytotoxicity., PMID:38240527
[ARL67156, a small-molecule CD39 inhibitor, enhances natural killer cell cytotoxicity against gastric cancer cells in vitro and in nude mice]., PMID:38189385
Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab., PMID:38185735
Donor aKIR genes influence the risk of EBV and CMV reactivation after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation., PMID:38081622
HLA-DPB1*13:01 associates with enhanced, and KIR2DS4*001 with diminished protection from developing severe COVID-19., PMID:37850268
Therapeutic Anti-KIR Antibody of 1-7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom., PMID:37762486
Understanding the heterogeneity of alloreactive natural killer cell function in kidney transplantation., PMID:37732256
Cattle killer immunoglobulin-like receptor expression on leukocyte subsets suggests functional divergence compared to humans., PMID:37634416
NK cells from COVID-19 positive patients exhibit enhanced cytotoxic activity upon NKG2A and KIR2DL1 blockade., PMID:37483595
Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells., PMID:37390222
Genotype List String 1.1: Extending the Genotype List String grammar for describing HLA and Killer-cell Immunoglobulin-like Receptor genotypes., PMID:37286192
NK cell defects: implication in acute myeloid leukemia., PMID:37228595
Influence of killer immunoglobulin-like receptors genes on the recurrence rate of ocular toxoplasmosis in Brazil., PMID:37018796
HHLA2 immune-regulatory roles in cancer., PMID:37011487
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial., PMID:36823323
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group., PMID:36822669
Malaria-driven expansion of adaptive-like functional CD56-negative NK cells correlates with clinical immunity to malaria., PMID:36696483
Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms., PMID:36633682
Understanding the killer-cell immunoglobulin like receptor polymorphism in retinoblastoma., PMID:36594723
Software update: Interpreting killer-cell immunoglobulin-like receptors from whole genome sequence data with PING., PMID:36565030
Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model., PMID:36386885
Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell-mediated antitumor immunity., PMID:36377656
Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia., PMID:36319065
HLA-B*27 Heavy Chain Homo-Oligomers Promote the Cytotoxicity of NK Cells via Activation of PI3K/AKT Signaling., PMID:36295572
ERAP/HLA-C and KIR Genetic Profile in Couples with Recurrent Implantation Failure., PMID:36293373
Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy., PMID:36261539
KIR-HLA gene diversities and susceptibility to lung cancer., PMID:36241658
Induced CD45 Proximity Potentiates Natural Killer Cell Receptor Antagonism., PMID:36169352
Killer-Cell Immunoglobulin-like Receptor Diversity in an Admixed South American Population., PMID:36139351
Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome., PMID:36046812
Donor selection based on NK alloreactivity for patients with hematological malignancies., PMID:35965181
KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy., PMID:35933091
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity., PMID:35768150
KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target., PMID:35687761
Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL., PMID:35500222
Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas., PMID:35474089
Characterization of KIR+ NK cell subsets with a monoclonal antibody selectively recognizing KIR2DL1 and blocking the specific interaction with HLA-C., PMID:35439359
Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes., PMID:35411634
Changes in the natural killer cell repertoire and function induced by the cancer immune adjuvant candidate IMMUNEPOTENT-CRP., PMID:35381435
For research use only. Not for human or drug use.
